Boulder, Colorado – September 22, 2026 -- Edgewise Therapeutics (Nasdaq: EWTX) disclosed preclinical data showing its lead cardiac drug candidate EDG-7500 improves heart relaxation while preserving systolic function, a mechanism the company says addresses a core driver of hypertrophic cardiomyopathy (HCM) that current therapies do not fully target.

Redmond – September 22, 2026 -- SystImmune Inc. has secured U.S. Food and Drug Administration clearance for its Investigational New Drug application for SI-B037, a bispecific antibody, marking the first time the company has built a regulatory submission entirely on New Approach Methodologies (NAMs) rather than traditional animal toxicology studies.

Uppsala, Sweden – September 22, 2026 -- Beactica Therapeutics AB has initiated IND-enabling studies for BEA-17, a first-in-class oral degrader targeting the epigenetic regulators LSD1 and CoREST, moving the glioblastoma therapy toward first-in-human trials.

Budapest – September 22, 2026 -- South Korean biopharmaceutical company PharmaResearch officially launched its REJURAN portfolio of polynucleotide (PN)-based skin boosters in Hungary, marking its latest expansion move in Europe's aesthetic medicine market.

Suzhou – September 22, 2026 -- Boomray Pharmaceuticals Co., Ltd. has signed an exclusive global license agreement with Novartis Pharma AG for an undisclosed preclinical radioligand therapy (RLT) asset, with total deal value reaching up to USD 900 million.

Milan – September 21, 2026 -- Tethis S.p.A. has completed the acquisition of the See.d software and engineering business unit from MACS S.r.l., gaining full control over intellectual property and engineering know-how behind its liquid biopsy platform. Alongside the transfer, Tethis signed a long-term manufacturing and supply agreement with Everex S.r.l., an Italian in-vitro diagnostic instrumentation maker, to handle production and future scale-up of the system.

Taipei – September 21, 2026 -- Merry Life Biomedical has advanced TML-6, a Taiwan-developed oral therapy for early Alzheimer's disease, into a global Phase 2 trial spanning 20 clinical sites across Taiwan, Sweden, and the United States, targeting approximately 210 participants.

Hong Kong – September 21, 2026 -- Akeso, Inc. (9926.HK) will present nearly 30 clinical studies of its bispecific antibodies at the European Society for Medical Oncology (ESMO) Congress in Madrid on October 23-27, 2026, including a Late-Breaking Abstract selected for the Presidential Symposium.

Pune, India – September 21, 2026 -- The global pharmaceutical logistics market is set to nearly double from approximately $100.0 billion in 2025 to $194.0 billion by 2034, expanding at a 7.7% compound annual growth rate, according to a new report from Maximize Market Research.

Houston – – September 21, 2026 -- Eli Lilly and Company (NYSE: LLY) has broken ground on a $6.5 billion manufacturing site in Houston, Texas, that will produce active pharmaceutical ingredients for Foundayo (orforglipron), the company's first synthetic oral GLP-1 medicine for weight management.